Skip to main content
Erschienen in: Calcified Tissue International 4/2016

22.06.2016 | Original Research

RANKL/Osteoprotegerin System and Bone Turnover in Hashimoto Thyroiditis

verfasst von: Ceyla Konca Degertekin, Ozlem Turhan Iyidir, Banu Aktas Yılmaz, Sehri Elbeg, Ozge Tugce Pasaoglu, Hatice Pasaoglu, Nuri Cakır, Metin Arslan

Erschienen in: Calcified Tissue International | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Hypothyroidism is associated with changes in bone metabolism. The impact of hypothyroidism and the associated autoimmunity on the mediators of bone turnover in Hashimoto’s thyroiditis (HT) is not known. In this study, we assessed the levels of OPG, RANKL, and IL-6 along with markers of bone formation as osteocalcin (OC) and markers of bone resorption as type 1 collagen C telopeptide (CTX) and tartrate-resistant acid phosphatase isoform 5b (TRAcP 5b) in 30 hypothyroid and 30 euthyroid premenopausal HT patients and 20 healthy premenopausal controls. We found that TRAcP 5b (p = 0.006), CTX (p = 0.01), OC (p = 0.017), and IL-6 (p < 0.001) levels were lower in the hypothyroid group compared to euthyroid HT patients and controls. OPG levels were higher (p < 0.001) and RANKL levels were lower (p = 0.021) in hypothyroid and euthyroid HT patients compared to controls. TSH was negatively correlated with IL-6 (rho = −0.434, p < 0.001), OC (rho = −0.313, p = 0.006), TRAcP 5b (rho = −0.335, p = 0.003), and positively correlated with OPG (rho = 0.248, p = 0.029). RANKL/OPG ratio was independently associated with the presence of HT. In conclusion, bone turnover is slowed down by hypothyroidism in premenopausal patients with HT. Thyroid autoimmunity might have a unique impact on OPG/RANKL levels apart from the resultant hypothyroidism.
Literatur
2.
Zurück zum Zitat Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79(5–6):243–253CrossRefPubMed Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79(5–6):243–253CrossRefPubMed
5.
Zurück zum Zitat Coindre JM, David JP, Riviere L, Goussot JF, Roger P, de Mascarel A, Meunier PJ (1986) Bone loss in hypothyroidism with hormone replacement: a histomorphometric study. Arch Intern Med 146(1):48–53CrossRefPubMed Coindre JM, David JP, Riviere L, Goussot JF, Roger P, de Mascarel A, Meunier PJ (1986) Bone loss in hypothyroidism with hormone replacement: a histomorphometric study. Arch Intern Med 146(1):48–53CrossRefPubMed
6.
Zurück zum Zitat Mosekilde L, Melsen F (1978) Morphometric and dynamic studies of bone changes in hypothyroidism. Acta pathol et microbiol Scand Sect A, Pathol 86(1):56–62 Mosekilde L, Melsen F (1978) Morphometric and dynamic studies of bone changes in hypothyroidism. Acta pathol et microbiol Scand Sect A, Pathol 86(1):56–62
7.
Zurück zum Zitat Kragstrup J, Melsen F, Mosekilde L (1981) Effects of thyroid hormone(s) on mean wall thickness of trabecular bone packets. Metab bone dis relat res 3(3):181–185CrossRefPubMed Kragstrup J, Melsen F, Mosekilde L (1981) Effects of thyroid hormone(s) on mean wall thickness of trabecular bone packets. Metab bone dis relat res 3(3):181–185CrossRefPubMed
8.
Zurück zum Zitat Vestergaard P, Mosekilde L (2002) Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid : Off J AmThyroid Assoc 12(5):411–419. doi:10.1089/105072502760043503 CrossRef Vestergaard P, Mosekilde L (2002) Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid : Off J AmThyroid Assoc 12(5):411–419. doi:10.​1089/​1050725027600435​03 CrossRef
9.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2005) Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 77(3):139–144. doi:10.1007/s00223-005-0068-x CrossRefPubMed Vestergaard P, Rejnmark L, Mosekilde L (2005) Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 77(3):139–144. doi:10.​1007/​s00223-005-0068-x CrossRefPubMed
10.
Zurück zum Zitat Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N, Thyroid Studies C (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313(20):2055–2065. doi:10.1001/jama.2015.5161 CrossRefPubMedPubMedCentral Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N, Thyroid Studies C (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313(20):2055–2065. doi:10.​1001/​jama.​2015.​5161 CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Giusti M, Cecoli F, Fazzuoli L, De Franchis V, Ceresola E, Ferone D, Mussap M, Minuto F (2007) Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. Metab, Clin Exp 56(5):699–707. doi:10.1016/j.metabol.2007.01.004 CrossRef Giusti M, Cecoli F, Fazzuoli L, De Franchis V, Ceresola E, Ferone D, Mussap M, Minuto F (2007) Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. Metab, Clin Exp 56(5):699–707. doi:10.​1016/​j.​metabol.​2007.​01.​004 CrossRef
12.
13.
Zurück zum Zitat Guang-da X, Hui-ling S, Zhi-song C, Lin-shuang Z (2005) Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J clin endocrinol metab 90(10):5765–5768. doi:10.1210/jc.2005-0562 CrossRefPubMed Guang-da X, Hui-ling S, Zhi-song C, Lin-shuang Z (2005) Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J clin endocrinol metab 90(10):5765–5768. doi:10.​1210/​jc.​2005-0562 CrossRefPubMed
14.
Zurück zum Zitat Nagasaki T, Inaba M, Jono S, Hiura Y, Tahara H, Shirakawa K, Onoda N, Ishikawa T, Ishimura E, Nishizawa Y (2005) Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J endocrinol/Eur Fed Endocr Soc 152(3):347–353. doi:10.1530/eje.1.01870 CrossRef Nagasaki T, Inaba M, Jono S, Hiura Y, Tahara H, Shirakawa K, Onoda N, Ishikawa T, Ishimura E, Nishizawa Y (2005) Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J endocrinol/Eur Fed Endocr Soc 152(3):347–353. doi:10.​1530/​eje.​1.​01870 CrossRef
15.
Zurück zum Zitat Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408(6812):600–605. doi:10.1038/35046102 CrossRefPubMed Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408(6812):600–605. doi:10.​1038/​35046102 CrossRefPubMed
17.
Zurück zum Zitat Pedersen OM, Aardal NP, Larssen TB, Varhaug JE, Myking O, Vik-Mo H (2000) The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid : Off J Am Thyroid Assoc 10(3):251–259CrossRef Pedersen OM, Aardal NP, Larssen TB, Varhaug JE, Myking O, Vik-Mo H (2000) The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid : Off J Am Thyroid Assoc 10(3):251–259CrossRef
18.
Zurück zum Zitat Ma R, Morshed S, Latif R, Zaidi M, Davies TF (2011) The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis. Thyroid : Off J AmThyroid Assoc 21(8):897–906. doi:10.1089/thy.2010.0457 CrossRef Ma R, Morshed S, Latif R, Zaidi M, Davies TF (2011) The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis. Thyroid : Off J AmThyroid Assoc 21(8):897–906. doi:10.​1089/​thy.​2010.​0457 CrossRef
19.
Zurück zum Zitat Varga F, Spitzer S, Klaushofer K (2004) Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcif Tissue Int 74(4):382–387. doi:10.1007/s00223-003-0033-5 CrossRefPubMed Varga F, Spitzer S, Klaushofer K (2004) Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcif Tissue Int 74(4):382–387. doi:10.​1007/​s00223-003-0033-5 CrossRefPubMed
20.
Zurück zum Zitat Botella-Carretero JI, Alvarez-Blasco F, San Millan JL, Escobar-Morreale HF (2007) Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. Eur J endocrinol/Eur Fed Endocr Soc 156(5):539–545. doi:10.1530/EJE-06-0649 CrossRef Botella-Carretero JI, Alvarez-Blasco F, San Millan JL, Escobar-Morreale HF (2007) Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. Eur J endocrinol/Eur Fed Endocr Soc 156(5):539–545. doi:10.​1530/​EJE-06-0649 CrossRef
21.
Zurück zum Zitat Giusti M, Cecoli F, Ghiara C, Rubinacci A, Villa I, Cavallero D, Mazzuoli L, Mussap M, Lanzi R, Minuto F (2007) Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma. Hormones (Athens) 6(4):304–313CrossRef Giusti M, Cecoli F, Ghiara C, Rubinacci A, Villa I, Cavallero D, Mazzuoli L, Mussap M, Lanzi R, Minuto F (2007) Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma. Hormones (Athens) 6(4):304–313CrossRef
24.
Zurück zum Zitat Hofbauer LC, Kluger S, Kuhne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE (2002) Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 86(4):642–650. doi:10.1002/jcb.10242 CrossRefPubMed Hofbauer LC, Kluger S, Kuhne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE (2002) Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 86(4):642–650. doi:10.​1002/​jcb.​10242 CrossRefPubMed
25.
Zurück zum Zitat Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390(6656):175–179. doi:10.1038/36593 CrossRefPubMed Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390(6656):175–179. doi:10.​1038/​36593 CrossRefPubMed
26.
Zurück zum Zitat Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ (2004) Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Investig 113(3):379–389. doi:10.1172/JCI19872 CrossRefPubMedPubMedCentral Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ (2004) Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Investig 113(3):379–389. doi:10.​1172/​JCI19872 CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC (1999) STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274(27):19301–19308CrossRefPubMed O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC (1999) STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274(27):19301–19308CrossRefPubMed
28.
Zurück zum Zitat Klecha AJ, Genaro AM, Lysionek AE, Caro RA, Coluccia AG, Cremaschi GA (2000) Experimental evidence pointing to the bidirectional interaction between the immune system and the thyroid axis. Int J Immunopharmacol 22(7):491–50010.1016/s0192-0561(00)00012-6. doi:CrossRefPubMed Klecha AJ, Genaro AM, Lysionek AE, Caro RA, Coluccia AG, Cremaschi GA (2000) Experimental evidence pointing to the bidirectional interaction between the immune system and the thyroid axis. Int J Immunopharmacol 22(7):491–50010.​1016/​s0192-0561(00)00012-6. doi:CrossRefPubMed
29.
Zurück zum Zitat Klecha AJ, Genaro AM, Gorelik G, Barreiro Arcos ML, Silberman DM, Schuman M, Garcia SI, Pirola C, Cremaschi GA (2006) Integrative study of hypothalamus-pituitary-thyroid-immune system interaction: thyroid hormone-mediated modulation of lymphocyte activity through the protein kinase C signaling pathway. J Endocrinol 189(1):45–55. doi:10.1677/joe.1.06137 CrossRefPubMed Klecha AJ, Genaro AM, Gorelik G, Barreiro Arcos ML, Silberman DM, Schuman M, Garcia SI, Pirola C, Cremaschi GA (2006) Integrative study of hypothalamus-pituitary-thyroid-immune system interaction: thyroid hormone-mediated modulation of lymphocyte activity through the protein kinase C signaling pathway. J Endocrinol 189(1):45–55. doi:10.​1677/​joe.​1.​06137 CrossRefPubMed
30.
Zurück zum Zitat Schoenfeld PS, Myers JW, Myers L, LaRocque JC (1995) Suppression of cell-mediated immunity in hypothyroidism. South Med J 88(3):347–349CrossRefPubMed Schoenfeld PS, Myers JW, Myers L, LaRocque JC (1995) Suppression of cell-mediated immunity in hypothyroidism. South Med J 88(3):347–349CrossRefPubMed
31.
Zurück zum Zitat Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs I, Tarjan G, Stern PH (1997) Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 82(1):78–81. doi:10.1210/jcem.82.1.3641 PubMed Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs I, Tarjan G, Stern PH (1997) Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 82(1):78–81. doi:10.​1210/​jcem.​82.​1.​3641 PubMed
32.
Zurück zum Zitat Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM (1999) Serum cytokines in thyrotoxicosis. J clin endocrinol metabol 84(2):435–439 Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM (1999) Serum cytokines in thyrotoxicosis. J clin endocrinol metabol 84(2):435–439
33.
Zurück zum Zitat Akalin A, Colak O, Alatas O, Efe B (2002) Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol 57(1):125–129CrossRef Akalin A, Colak O, Alatas O, Efe B (2002) Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol 57(1):125–129CrossRef
Metadaten
Titel
RANKL/Osteoprotegerin System and Bone Turnover in Hashimoto Thyroiditis
verfasst von
Ceyla Konca Degertekin
Ozlem Turhan Iyidir
Banu Aktas Yılmaz
Sehri Elbeg
Ozge Tugce Pasaoglu
Hatice Pasaoglu
Nuri Cakır
Metin Arslan
Publikationsdatum
22.06.2016
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 4/2016
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-016-0163-1

Weitere Artikel der Ausgabe 4/2016

Calcified Tissue International 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.